510(k) · Cleared
Recalled · Class II · 2023FilmArray Pneumonia Panel
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Biofire Diagnostics, LLC · QDP Respiratory Panel
Cleared on Nov 9, 2018 as substantially equivalent to DEN170047 (Curetis GmbH, 2018) after a 210-day review. Its family tree reaches back 1 generation to 2018. 2 later devices descend from it. It has been recalled 4 times.
- Decided
- Nov 9, 2018
- Review
- 210 days
- Class
- Class II
- Product code
- QDP
- Recalls
- 4
- Predicates
- 1
Its longest line of descent runs back 1 generation to DEN170047 (2018). 2 later devices descend from it, 1 citing it directly.
- Root · 1 generation backDEN170047 Curetis Unyvero LRT ApplicationCuretis GmbH · 2018
- This deviceK180966 FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2018
- Descendant · cites it directly · 1 of its ownK212727 FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2021 · Recalled
- Descendant · 2 generations on · 0 of its ownK243222 BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel)…Biofire Diagnostics, LLC (Biomerieux) · 2024 · Recalled
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | DEN170047 | Curetis Unyvero LRT Application | Curetis GmbH | 2018 | — |
| 0 (this device) | K180966 | FilmArray Pneumonia Panel | Biofire Diagnostics, LLC | 2018 | — |
| +1 | K212727 | FilmArray Pneumonia Panel | Biofire Diagnostics, LLC | 2021 | 1 |
| +2 | K243222 | BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE®… | Biofire Diagnostics, LLC (Biomerieux) | 2024 | 3 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2021 | 1 | 0 |
| 2024 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in QDP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new QDP device
- #1 K212727 FilmArray Pneumonia Panelscore 3.4 · 2 generations · no Class I recall
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | DEN170047 | Curetis Unyvero LRT ApplicationSummary page 7…Name: Device to detect and identify microorganisms and associated resistance marker nucleic acids directly in respiratory specimens Product Code: QDP Predicate Device: DEN170047 – Curetis Unyvero LRT Application Intended Use: The FilmArray® Pneumonia Panel is a multiplexed nucleic acid test intended for u… | 2018 |
What descends from it? (2)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K212727 | FilmArray Pneumonia Panel | 2021 | 1 |
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Dec 14, 2023 | Class II | Z-0994-2024 | Under Investigation by firm | Their is a potential for false positive results when using Pneumonia panel. |
| May 8, 2023 | Class II | Z-2440-2023 | Process design | Due to manufacturing issue, panels may result in false negative results. |
| Jun 7, 2021 | Class II | Z-2039-2021 | Under Investigation by firm | Due to real-time stability study failures resulting in increase rate of false negative results between the 6 to 12 month expiry time-frame. |
| Apr 16, 2021 | Class II | Z-1944-2021 | Under Investigation by firm | Elevated rates of false positive/false negative and control failures while using the Pneumonia Panel, due to issues identified in the manufacturing process. |
No ancestor or descendant has a Class I recall.
What does this lineage say?
How does its category compare?
All QDP devicesQDP Respiratory Panel: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.
FDA decisions per year · QDP
1in 2021
2026 to Oct 25, outlined.
Median 510(k) review, days · QDP
Too few QDP 510(k)s in any year since 2007 to give a median.
Recalls per year · QDP
1so far in 2026, the most since 2007
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · QDP
No MAUDE report names QDP since 2007.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 1 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 1 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 1 | — |
What is it indicated for?
The FilmArray® Pneumonia Panel is a multiplexed nucleic acid test intended for use with FilmArray®, FilmArray® 2.0, or FilmArray® Torch systems for the simultaneous detection and identification of multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL)…
Read the full statement (695 words)
The FilmArray® Pneumonia Panel is a multiplexed nucleic acid test intended for use with FilmArray®, FilmArray® 2.0, or FilmArray® Torch systems for the simultaneous detection and identification of multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals suspected of lower respiratory tract infection.
The following bacteria are reported semi-quantitatively with bins representing approximately 104 105, 10”6, or >10"7 genomic copies of bacterial nucleic acid per milliliter (copies/mL) of specimen, to aid in estimating relative abundance of nucleic acid from these common bacteria within a specimen:
Bacteria reported with bins of 104 10"5, 1076, or 210”7 copies/mL
* Acinetobacter calcoaceticus-baumannii complex
* Enterobacter cloacae complex
* Escherichia coli
* Haemophilus influenzae
* Klebsiella aerogenes
* Klebsiella oxytoca
* Klebsiella pneumoniae group
* Moraxella catarrhalis
* Proteus spp.
* Pseudomonas aeruginosa
* Serratia marcescens
* Staphylococcus aureus
* Streptococcus agalactiae
* Streptococcus pneumoniae
* Streptococcus pyogenes
The following atypical bacteria, viruses, and antimicrobial resistance genes are reported qualitatively:
Atypical Bacteria
* Chlamydia pneumoniae
* Legionella pneumophila
* Mycoplasma pneumoniae
Viruses
* Adenovirus
* Coronavirus
* Human Metapneumovirus
* Human Rhinovirus/Enterovirus
* Influenza A
* Influenza B
* Parainfluenza Virus
* Respiratory Syncytial Virus
Antimicrobial Resistance Genes
CTX-M
IMP
KPC
NDM
OXA-48-like
VIM
mecA/C and MREJ
The detection and identification of specific viral and bacterial nucleic acids, as well as the estimation of relative abundance of nucleic acid from common bacterial analytes, within specimens collected from individuals exhibiting signs and/or symptoms of a respiratory infection, aids in the diagnosis of lower respiratory infection if used in conjunction with other clinical and epidemiological information. The results of this test should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.
Negative results in the setting of a respiratory illness may be due to infection with pathogens that are not detected by this test, pathogens below the limit of detection, or in the case of bacterial analytes, present at levels below the lowest reported 1074 copies/mL bin. Detection of analytes does not rule out co-infection with other organisms; the agent(s) detected by the FilmArray Pneumonia Panel may not be the definite cause of disease. Additional laboratory testing (e.g. bacterial and viral culture, immunofluorescence, and radiography) may be necessary when evaluating a patient with possible lower respiratory tract infection.
Detection of bacterial nucleic acid may be indicative of colonizing or normal respiratory flora and may not indicate the causative agent of pneumonia. Semi-quantitative bin (copies/mL) results generated by the FilmArray Pneumonia Panel are not equivalent to CFU/mL and do not consistently correlate with the quantity of bacterial analytes compared to CFU/mL. For specimens with multiple bacteria detected, the relative abundance of nucleic acids (copies/mL) may not correlate with the relative abundance of bacteria as determined by culture (CFU/mL). Clinical correlation is advised to determine significance of semi-quantitative bin (copies/mL) for clinical management.
The antimicrobial resistance gene detected may or may not be associated with the agent(s) responsible for disease. Negative results for these antimicrobial resistance gene assays do not indicate susceptibility to corresponding classes of antimicrobials, as multiple mechanisms of antimicrobial resistance exist.
Antimicrobial resistance can occur via multiple mechanisms. A "Not Detected" result for a genetic marker of antimicrobial resistance does not indicate susceptibility to associated antimicrobial drugs or drug classes. A "Detected" result for a genetic marker of antimicrobial resistance cannot be definitively linked to the microorganism(s) detected. Culture is required to obtain isolates for antimicrobial susceptibility testing, and FilmArray Pneumonia Panel results should be used in conjunction with culture results for determination of bacterial susceptibility or resistance.
Due to the genetic similarity between human rhinovirus and enterovirus, the test cannot reliably differentiate them. A positive Rhinovirus/Enterovirus result should be followed up using an alternate method (e.g., cell culture or sequence analysis) if differentiation is required.
Culture is required to identify pathogens not detected by the FilmArray Pneumonia Panel, to further speciate analytes in genus, complex, or group results if desired, to identify bacterial pathogens present below the 10”4 copies/mL bin if desired, and for antimicrobial susceptibility testing.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K180966 · printed Nov 5, 2026
Cite this page
510(k) Report. “K180966: FilmArray Pneumonia Panel.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K180966
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026